Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II three-cohort trial of oral BMS-275183 in pretreated advanced NSCLC
2005-005099-33Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2006
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bms-275183 in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Tumor response rate (primary efficacy endpoint). Started Aug 2006; status: completed.
02
Drugs
bms-275183
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-005099-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005099-33.